M.A. Pessi

1.4k total citations
42 papers, 1.0k citations indexed

About

M.A. Pessi is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Surgery. According to data from OpenAlex, M.A. Pessi has authored 42 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 14 papers in Public Health, Environmental and Occupational Health and 7 papers in Surgery. Recurrent topics in M.A. Pessi's work include Colorectal Cancer Treatments and Studies (15 papers), Palliative Care and End-of-Life Issues (14 papers) and Genetic factors in colorectal cancer (7 papers). M.A. Pessi is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Palliative Care and End-of-Life Issues (14 papers) and Genetic factors in colorectal cancer (7 papers). M.A. Pessi collaborates with scholars based in Italy, Netherlands and Ukraine. M.A. Pessi's co-authors include Roberto Labianca, Carla Ripamonti, Giordano Beretta, Stefania Mosconi, Laura Milesi, Guido Miccinesi, Alice Maruelli, Antonello Quadri, Tiziana Prochilo and J. Wils and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and European Journal of Cancer.

In The Last Decade

M.A. Pessi

41 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.A. Pessi Italy 18 511 183 168 159 152 42 1.0k
Maha Hussain United States 16 569 1.1× 264 1.4× 207 1.2× 163 1.0× 120 0.8× 23 1.2k
F Pannuti Italy 23 766 1.5× 233 1.3× 178 1.1× 213 1.3× 142 0.9× 122 1.5k
Roger Favre France 17 341 0.7× 193 1.1× 171 1.0× 219 1.4× 80 0.5× 44 931
Nadia Obi Germany 19 516 1.0× 114 0.6× 144 0.9× 139 0.9× 77 0.5× 63 1.0k
Burhan Savaş Türkiye 18 438 0.9× 113 0.6× 183 1.1× 238 1.5× 85 0.6× 63 954
M. S. Vidyasagar India 21 590 1.2× 497 2.7× 201 1.2× 214 1.3× 162 1.1× 61 1.6k
Junta Tanaka Japan 18 649 1.3× 209 1.1× 146 0.9× 326 2.1× 98 0.6× 57 1.6k
Sophie Pilleron United Kingdom 18 440 0.9× 178 1.0× 252 1.5× 141 0.9× 99 0.7× 61 1.4k
Janise M. Roh United States 19 720 1.4× 145 0.8× 146 0.9× 168 1.1× 87 0.6× 80 1.2k
Arafat Tfayli Lebanon 21 522 1.0× 229 1.3× 122 0.7× 364 2.3× 73 0.5× 95 1.3k

Countries citing papers authored by M.A. Pessi

Since Specialization
Citations

This map shows the geographic impact of M.A. Pessi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.A. Pessi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.A. Pessi more than expected).

Fields of papers citing papers by M.A. Pessi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.A. Pessi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.A. Pessi. The network helps show where M.A. Pessi may publish in the future.

Co-authorship network of co-authors of M.A. Pessi

This figure shows the co-authorship network connecting the top 25 collaborators of M.A. Pessi. A scholar is included among the top collaborators of M.A. Pessi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.A. Pessi. M.A. Pessi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ripamonti, Carla, et al.. (2015). Is it possible to encourage hope in non-advanced cancer patients? We must try. Annals of Oncology. 27(3). 513–519. 24 indexed citations
3.
Ripamonti, Carla, Massimo Costantini, Fabio Pellegrini, et al.. (2014). The effectiveness of the quality program Pac-IficO to improve pain management in hospitalized cancer patients: a before-after cluster phase II trial. BMC Palliative Care. 13(1). 15–15. 5 indexed citations
4.
Pessi, M.A., Nicoletta Zilembo, Eva Regina Haspinger, et al.. (2013). Targeted therapy-induced diarrhea: A review of the literature. Critical Reviews in Oncology/Hematology. 90(2). 165–179. 39 indexed citations
5.
Ripamonti, Carla, Elena Bandieri, M.A. Pessi, et al.. (2013). The Edmonton Symptom Assessment System (ESAS) as a screening tool for depression and anxiety in non-advanced patients with solid or haematological malignancies on cure or follow-up. Supportive Care in Cancer. 22(3). 783–793. 35 indexed citations
6.
7.
Miccinesi, Guido, M.A. Pessi, Alice Maruelli, et al.. (2012). Is the Spiritual Life of Cancer Patients a Resource to be taken into Account by Professional Caregivers from the Time of Diagnosis?. Tumori Journal. 98(1). 158–161. 5 indexed citations
8.
Ripamonti, Carla, et al.. (2011). Progetti “ospedale senza dolore”: analisi della realtà italiana prima della legge 38. CNR Solar (Scientific Open-access Literature Archive and Repository) (Consiglio Nazionale delle Ricerche). 4 indexed citations
9.
Labianca, Roberto, Giordano Beretta, Laura Milesi, et al.. (2010). Colon cancer. Critical Reviews in Oncology/Hematology. 74(2). 106–133. 308 indexed citations
10.
Labianca, Roberto, Laura Milesi, Stefania Mosconi, et al.. (2007). The role of adjuvant chemotherapy in colon cancer. Surgical Oncology. 16. 93–96. 10 indexed citations
11.
Labianca, Roberto, Giordano Beretta, Stefania Mosconi, Laura Milesi, & M.A. Pessi. (2005). Colorectal cancer: screening. Annals of Oncology. 16. ii127–ii132. 23 indexed citations
12.
Labianca, Roberto, Giordano Beretta, Stefania Mosconi, M.A. Pessi, & Laura Milesi. (2005). The development of clinical research in CRC. Annals of Oncology. 16. iv37–iv43. 11 indexed citations
13.
Sobrero, Alberto, Alfredo Guglielmi, Massimo Círillo, et al.. (2001). 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. British Journal of Cancer. 84(8). 1023–1028. 12 indexed citations
14.
Labianca, Roberto, Giordano Beretta, & M.A. Pessi. (2001). Colorectal Cancer. Drugs. 61(12). 1751–1764. 25 indexed citations
15.
Sobrero, Alberto, Alberto Zaniboni, Giovanni Luca Frassineti, et al.. (2000). Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study. Annals of Oncology. 11(11). 1413–1420. 15 indexed citations
17.
Cascinu, Stefano, Sandro Barni, Roberto Labianca, et al.. (1999). A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer. 80(10). 1595–1598. 68 indexed citations
18.
Labianca, Roberto, et al.. (1997). Errata: Treatment of colorectal cancer: Current guidelines and future prospects for drug therapy (Drugs (1997) 53 (593-607)). Drugs. 54(1). 9 indexed citations
19.
Labianca, Roberto, et al.. (1997). Treatment of Colorectal Cancer. Drugs. 53(4). 593–607. 60 indexed citations
20.
Cascinu, Stefano, Sandro Barni, Roberto Labianca, et al.. (1997). Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. Supportive Care in Cancer. 5(4). 314–317. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026